[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584969":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":23,"locations":31,"responsibleParty":82,"collaborators":10,"id":85,"slug":10,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":10,"enrollmentInfo":94,"targetDuration":97,"studyType":98,"phases":10,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Hospital Universitario 12 de Octubre","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"A",null,"Patients with arrhytmia-induced cardiomyopathy criteria",{"label":13,"type":10,"description":14,"interventionNames":10},"B","Patients without arrhytmia-induced cardiomyopathy criteria",[16,20],{"name":17,"affiliation":18,"role":19},"Martín Negreira-Caamaño, MD, PhD","Cardiology department, 12 de Octubre University Hospital","STUDY_DIRECTOR",{"name":21,"affiliation":22,"role":19},"Rafael Salguero-Bodes, MD","Cardiology Department, 12 de Octubre University Hospital",[24,28],{"name":17,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+34913908000","martin.negcam@gmail.com",{"name":29,"role":25,"phone":26,"phoneExt":10,"email":30},"Daniel Rodríguez-Muñoz, MD, PhD","daniel.rodriguez.mnz@gmail.com",[32,50,62,76],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Ciudad Real General University Hospital","RECRUITING","Ciudad Real","Castille-La Mancha","15004","Spain",{"type":40,"coordinates":41},"Point",[42,43],-3.92907,38.98626,{"lat":43,"lon":42},[46],{"name":47,"role":25,"phone":48,"phoneExt":10,"email":49},"Jesús Piqueras-Flores, MD, PhD","926278000","jpiqueras@sescam.jccm.es",{"facility":51,"status":34,"city":52,"state":52,"zip":53,"country":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"12 de Octubre University Hospital","Madrid","28004",{"type":40,"coordinates":55},[56,57],-3.70256,40.4165,{"lat":57,"lon":56},[60],{"name":61,"role":25,"phone":26,"phoneExt":10,"email":27},"Martín Negreira Caamaño, MD, PhD",{"facility":63,"status":64,"city":65,"state":10,"zip":10,"country":38,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Albacete University Hospital Complex","NOT_YET_RECRUITING","Albacete",{"type":40,"coordinates":67},[68,69],-1.85643,38.99424,{"lat":69,"lon":68},[72],{"name":73,"role":25,"phone":74,"phoneExt":10,"email":75},"Sofía Calero-Nuñez, MD, PhD","967597100","sofia.caleron@gmail.com",{"facility":77,"status":78,"city":52,"state":10,"zip":10,"country":38,"cosmosGeoPoint":79,"geoPoint":81,"contacts":10},"Ramón y Cajal University Hospital","ACTIVE_NOT_RECRUITING",{"type":40,"coordinates":80},[56,57],{"lat":57,"lon":56},{"type":83,"investigatorFullName":17,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","MD, PhD","100584969",false,"NCT06896266","Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy","Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy","UNCHAINED-I","Inclusion Criteria:\n\n* Presence of atrial fibrillation or atrial flutter not self-limited.\n* Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \\\u003C50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \\\u003C50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.\n* Signature of informed consent.\n* Ability to understand and accept participation in the study.\n\nExclusion Criteria:\n\n* Refusal of informed consent.\n* Legal or juridical incapacity.\n* Age \\\u003C18 years.\n* Life expectancy less than 1 year.\n* Impossibility of a follow-up of at least 6 months.\n* Presence of a ventricular rate \\>140 beats per minute, limiting the validity of imaging measurements.\n* Presence of known factors causing systolic ventricular dysfunction:\n\n  * Prior cardiomyopathy diagnosis.\n  * Severe mitral or aortic valve disease.\n  * Non-revascularizable ischemic heart disease.\n  * Context of peri-resuscitation cardiopulmonary care.\n  * Abusive alcohol consumption, defined as \\>80 grams of ethanol or \\>7 standard alcoholic beverages per day.\n  * Active treatment with chemotherapeutic agents or radiation therapy to the thorax.\n  * Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.","ALL","18 Years",{"count":95,"type":96},109,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:\n\nI. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?",[101,102,103],"Arrhythmia","Cardiomyopathy","Arrhythmia-induced Cardiomyopathy (AiCM)",[105,106,107,108,109,110],"atrial fibrillation","atrial flutter","heart failure","arrhythmia-induced cardiomyopathy","cardiomyopathy","genetics","2025-05-09",{"date":113,"type":114},"2025-05-14","ACTUAL",{"date":116,"type":114},"2024-12-01",{"date":118,"type":96},"2026-12",{"name":5,"class":6},4]